<DOC>
	<DOCNO>NCT00721032</DOCNO>
	<brief_summary>Ventricular tachycardia ( VT ) morbid arrhythmia responsible many sudden death ICD shock . Despite much progress treatment arrhythmia , VT remain therapeutic challenge . Most patient VT implantable cardioverter defibrillator ( ICD ) secondary prevention sudden cardiac death , however , ICD merely treat VT , prevent VT . In patient recurrent VT ICD shock , two strategy available decrease burden VT . The first antiarrhythmic drug , second VT ablation . The aim study compare efficacy antiarrhythmic drug VT ablation guide MRI . VT sometimes suppress antiarrhythmic medication , however , often ineffective , carry high burden side effect . Many form VT cured selective destruction critical electrical pathway catheter ablation . A major limitation ablation VT , however , time require localize scar tissue important pathway target lesion . Magnetic resonance image obtain reliable image scar location within ventricle . Recent advance electroanatomical map system allow operator import pre-acquired image map system . The aim study examine feasibility import historic MRI scar map ventricles electroanatomical system use image guide catheter ablation , compare antiarrhythmic drug suppression VT. We suspect MRI guidance especially useful patient `` unstable '' VT , i.e . VT cause abrupt drop blood pressure , thus maintain EP lab map entrainment purpose . Patients refer VT ablation ICDs . Through previously complete animal work ( Circulation 2004 ; 110 ( 5 ) : 475-82 ) human trial ( 2006 Sep 19 ; 114 ( 12 ) :1277-84 ) demonstrate safety MRI set pacemaker implantable defibrillator use appropriate precaution . Through careful device program use MRI sequence limit energy exposure ( specific absorption rate &lt; 2 W/kg ) study pre procedural myocardial anatomy patient enrol study . The primary endpoint lack VT document implantable defibrillator ( present ) interrogation Holter monitor 6 month post ablation . The secondary endpoint comparison inducible arrhythmia end procedure , procedure time , comparison endocardial voltage mapping scar delay enhancement MRI image , complication study arm .</brief_summary>
	<brief_title>Anti-arrhythmic Medication v. MRI-Merge Ablation Treatment Ventricular Tachycardia</brief_title>
	<detailed_description />
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<criteria>Inclusion : Current treatment amiodarone Ischemic nonischemic cardiomyopathy Monomorphic ventricular tachycardia cycle length , &gt; 1 occurrence cycle length morphology , least one episode need sufficient duration result shock . No contraindication titration med VT RFA Exclusion : Primary antiarrhythmic medication amiodarone Amiodarone dose 600 mg daily high Polymorphic VT culprit rhythm History metal exposure ( weld ) Pregnant woman Recent myocardial infarction Planned coronary revascularization Implantable cardiac device previously test safety set MRI GFR &lt; 30 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Ventricular tachycardia ( VT )</keyword>
	<keyword>Implantable cardioverter-defibrillator ( ICD )</keyword>
	<keyword>Ablation</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Electrophysiology study</keyword>
</DOC>